In a phase I/II clinical trial, mature DCs charged with HCC antigens such as αFP, glypican-3 (GPC-3) and melanoma antigen gene-1 (MAGE-1) were administered as a vaccine to patients with advanced HCC. Here, AFP is linked to hepatocellular carcinoma.